Healthcare provider profile · identity verified

Padmavathi Sainath, MD

Hospitalist · REDWOOD CITY, CA · NPI 1023182334

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	315	39
Furosemide	Furosemide	234	26
Gabapentin	Gabapentin	213	24
Amlodipine Besylate	Amlodipine Besylate	211	29
Lisinopril	Lisinopril	193	20
Omeprazole	Omeprazole	189	11
Sertraline Hcl	Sertraline Hcl	172	12
Levothyroxine Sodium	Levothyroxine Sodium	171	20
Potassium Chloride	Potassium Chloride	140	13
Duloxetine Hcl	Duloxetine Hcl	120	suppressed
Clopidogrel	Clopidogrel Bisulfate	110	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	106	16
Digoxin	Digoxin	89	suppressed
Hydralazine Hcl	Hydralazine Hcl	85	11
Simvastatin	Simvastatin	83	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	71	12
Tamsulosin Hcl	Tamsulosin Hcl	67	suppressed
Mirtazapine	Mirtazapine	66	suppressed
Donepezil Hcl	Donepezil Hcl	65	suppressed
Citalopram Hbr	Citalopram Hydrobromide	62	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	61	suppressed
Losartan Potassium	Losartan Potassium	55	17
Levetiracetam	Levetiracetam	53	suppressed
Metoprolol Succinate	Metoprolol Succinate	52	14
Escitalopram Oxalate	Escitalopram Oxalate	51	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	50	suppressed
Atenolol	Atenolol	49	suppressed
Famotidine	Famotidine	49	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	48	suppressed
Jardiance	Empagliflozin	47	suppressed
Aripiprazole	Aripiprazole	46	suppressed
Lovastatin	Lovastatin	46	suppressed
Pravastatin Sodium	Pravastatin Sodium	46	suppressed
Spiriva Respimat	Tiotropium Bromide	44	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	41	suppressed
Chlorthalidone	Chlorthalidone	40	suppressed
Oxycodone Hcl	Oxycodone Hcl	39	13
Xarelto	Rivaroxaban	36	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	35	suppressed
Eliquis	Apixaban	34	suppressed
Montelukast Sodium	Montelukast Sodium	33	suppressed
Albuterol Sulfate	Albuterol Sulfate	32	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	31	13
Pregabalin	Pregabalin	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	29	suppressed
Latanoprost	Latanoprost	29	12
Metformin Hcl	Metformin Hcl	28	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Sucralfate	Sucralfate	24	suppressed
Trazodone Hcl	Trazodone Hcl	23	suppressed
Baclofen	Baclofen	21	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	21	suppressed
Cephalexin	Cephalexin	21	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Nystatin	Nystatin	19	suppressed
Lorazepam	Lorazepam	18	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	18	suppressed
Prednisone	Prednisone	18	suppressed
Glipizide	Glipizide	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Humulin R	Insulin Regular, Human	16	suppressed
Topiramate	Topiramate	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Glipizide Er	Glipizide	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Finasteride	Finasteride	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Procrit	Epoetin Alfa	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	12	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Anastrozole	Anastrozole	11	suppressed
Calcium Acetate	Calcium Acetate	11	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	11	suppressed
Letrozole	Letrozole	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error